PMEF
GPCR icon

Point72 Middle East FZE’s Structure Therapeutics GPCR Stock Holding History

Point72 Middle East FZE’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8,474
Closed -$202K – 1747
2023
Q1 		$202K Buy
+8,474
New +$199K 0.01% 948

Other funds holding GPCR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Point72 Middle East FZE's GPCR Position: Q2 2023 in Review

Point72 Middle East FZE sold out of Structure Therapeutics (GPCR) in Q2 2023, closing a stake of 8,474 shares — an estimated $202K sold.

Point72 Middle East FZE first reported a position in GPCR in Q1 2023 and held it in 1 quarter. The position peaked at $202K in Q1 2023. 48 funds tracked by Wall St. Rank hold GPCR as of Q2 2023.

  • Point72 Middle East FZE reported no remaining Structure Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 8,474 Structure Therapeutics shares in Q2 2023, an estimated $202K.
  • Point72 Middle East FZE first reported a position in Structure Therapeutics in Q1 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Structure Therapeutics position peaked at $202K in Q1 2023.
  • 48 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.